REVIVA PHARMACEUTICALS HOLDINGS, INC.
RVPHNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$20.2M | −$30.8M | −$39.5M | −$19.3M | −$10.1M | −$2.4M |
| Net income | −$19.9M | −$29.9M | −$39.3M | −$19.0M | −$8.5M | −$3.8M |
| Total assets | $15.9M | $15.5M | $23.7M | $18.9M | $31.4M | $8.8M |
| Total liabilities | $7.3M | $14.7M | $18.0M | $6.5M | $2.7M | $3.3M |
| Equity | $8.6M | $812,572 | $5.7M | $17.6M | $28.7M | $5.5M |
| EPS (diluted) | $-5.48 | $-17.73 | $-1.65 | $-1.02 | $-0.58 | — |
| Shares out. | 46.7M | 27.9M | 20.5M | 15.1M | 9.2M | 7.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −229.7%
- Return on assets
- −124.8%
- Return on capital (ROCE)
- −233.6%
- Liabilities / assets
- 45.7%
- Debt / equity
- 0.84×
- Book value / share
- $0.19
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -41.75distress
- Accruals / assets
- 29.7%high accruals
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 2 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 31, 2025
- NT 10-Kmissed a reporting deadline ↗Apr 2, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Cvi Investments, Inc.Passive (13G)May 15, 2026
- Barclays PlcPassive (13G)May 14, 2026
- Ubs Group AgPassive (13G)May 7, 2026
- Integrated Core Strategies (Us) LlcPassive (13G)Mar 30, 2026
- Saxena ParagActivist (13D)Mar 24, 2026
- 683 Capital Management, LlcPassive (13G)Feb 17, 2026
- Bhat LaxminarayanActivist (13D)Sep 24, 2025
- Tang Capital Management LlcPassive (13G)Aug 14, 2025
- Highbridge Capital Management LlcPassive (13G)Aug 14, 2025
- Schonfeld Strategic Advisors LlcPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.2M | 1.0 | -34.7% |
| Apr 30, 2026 | 1.9M | 4.9 | +30.6% |
| Apr 15, 2026 | 1.4M | 1.9 | -22.1% |
| Mar 31, 2026 | 1.8M | 1.3 | +126.6% |
| Mar 13, 2026 | 809,588 | 3.2 | -95.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Regulation FD disclosureMay 13, 2026
- Delisting / listing-standard notice · Other material eventMay 13, 2026
- Regulation FD disclosure · Other material eventApr 15, 2026
- Results of operations · Regulation FD disclosureMar 30, 2026
- Entered a material agreement · Regulation FD disclosureMar 19, 2026
- Modified shareholder rights · Amended charter or bylaws · Other material eventMar 5, 2026
- Delisting / listing-standard notice · Other material eventJan 23, 2026
- Amended charter or bylaws · Shareholder vote · Regulation FD disclosure · Other material eventDec 23, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13GMay 14, 2026
- 10-QFORM 10-QMay 13, 2026
- 8-KFORM 8-KMay 13, 2026
- 8-KFORM 8-KMay 13, 2026
- SCHEDULE 13GMay 7, 2026
- 8-KFORM 8-KApr 15, 2026
- SCHEDULE 13GMar 30, 2026
- S-8FORM S-8Mar 30, 2026
- 8-KFORM 8-KMar 30, 2026
- 10-KFORM 10-KMar 30, 2026
- SCHEDULE 13GMar 25, 2026
- SCHEDULE 13D/AMar 24, 2026
- 4FORM 4Mar 20, 2026
- 4FORM 4Mar 20, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.